Emgality ® (galkanezumab)

För fullständig produktresumé för Emgality® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Emgality® ▼ (galcanezumab): Enhet: Information om luftbubblor

Det är normalt att ha bubblor i pennan eller sprutan. Läkemedlet injiceras under huden (subkutan injektion).

Additional Information

The presence of the air bubble is due to the syringe manufacturing process. It will not cause harm or affect the accuracy of the dose.1

Patients should not try to remove or expel the air bubble in the device. Removal of the air bubble before injecting is not necessary and not recommended.1

The instructions for using the pen or syringe included with the Package Leaflet, must be followed carefully. The pre-filled pen and pre-filled syringe is for total use only.2

After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate.3

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Emgality [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.

3. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M02 13


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss